RxDoctor Payments Data

Warren Fields, MD

Internal Medicine · Mystic, CTNPI 1821083999

Payments from drug & device makers

$1,901in general payments, 2019–2025

Across 35 payments — averaging $54.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$411
  • GSK$387
  • Boehringer Ingelheim$294
  • Nevro Corp.$279
  • Novo Nordisk$204
  • Boston Scientific$108
  • plus $218 from 5 others

What the payments were for

  • Food & beverage$1,86698%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,901 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$202,513
Medicare patients
617
Services billed
2,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin120$140,662
EliquisApixaban115$97,232
OzempicSemaglutide67$75,607
JanuviaSitagliptin Phosphate43$50,775
OxycontinOxycodone Hcl42$25,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$18,942
XareltoRivaroxaban19$16,970
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$14,253
MyrbetriqMirabegron16$13,633
Breo ElliptaFluticasone/Vilanterol14$10,486
SymbicortBudesonide/Formoterol Fumarate23$8,849
Dexlansoprazole DrDexlansoprazole17$6,267
Atorvastatin Calcium434$5,371
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$4,979
Potassium Chloride75$3,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$294$140,662120 claims
Novo NordiskOzempic$204$75,60767 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$387$43,68139 claims
AstraZenecaSymbicort$411$8,84923 claims
AbbVieSynthroid$74$3,80857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Mystic

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →